Amgen or Biogen: Which Biotech Stock Appears Better Poised?

Industry
โดย Zacks Investment Research·Read original
Summary · why it matters

Amgen and Biogen are two of the world's largest biotech companies, and a comparison of their fundamentals, growth outlook, and risks suggests Amgen currently presents the more attractive investment opportunity. Amgen offers a diversified portfolio with more than a dozen blockbuster products, strong cash generation, and dividend income, while Biogen is in the midst of a major portfolio transition as its multiple sclerosis franchise declines. Biogen's newer drugs, including Leqembi, Skyclarys, Qalsody, and Zurzuvae, are not yet sufficient to offset near-term revenue declines, and increased costs from recent acquisitions have led to downward earnings estimate revisions. Amgen's key medicines and new biosimilar launches are driving top-line growth, though it faces a significant patent-expiration overhang with products like Prolia, Xgeva, Enbrel, and Otezla accounting for roughly 30% of 2025 product sales. Both stocks carry a Zacks Rank of 3, or Hold, but Amgen's broader commercial portfolio and more stable outlook make it the preferred choice.

Impact on stocks 4

Biotech & Genomic Medicine± Mixed · 4 stocks
Amgen Inc
AMGN
▲ PositiveCapitalrelevance

Article compares Amgen favorably to Biogen, citing diversified portfolio, strong cash generation, and dividend income, making it the preferred investment.

Biogen Inc
BIIB
▼ NegativeCapitalrelevance

Article notes Biogen's multiple sclerosis franchise decline, insufficient new drug revenue, and downward earnings estimate revisions.

© 2026 MarketDXNews